Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
1.490
+0.080 (5.67%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Cyclerion Therapeutics Revenue
Cyclerion Therapeutics had revenue of $875.00K in the quarter ending September 30, 2025, with 351.03% growth. This brings the company's revenue in the last twelve months to $2.86M, up 1,371.65% year-over-year. In the year 2024, Cyclerion Therapeutics had annual revenue of $2.00M.
Revenue (ttm)
$2.86M
Revenue Growth
+1,371.65%
P/S Ratio
1.92
Revenue / Employee
$2,855,000
Employees
1
Market Cap
5.67M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCYCN News
- 20 days ago - Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - GlobeNewsWire
- 2 months ago - Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 5 months ago - Cyclerion Therapeutics, Inc. - Pre Recorded Special Call - Seeking Alpha
- 5 months ago - Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company - GlobeNewsWire
- 1 year ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 1 year ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 2 years ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire